Bayer
Whippany
New Jersey
United States
914 articles about Bayer
-
Century Therapeutics Launches With USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy Platform - July 1, 2019
7/1/2019
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies
-
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform
7/1/2019
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies
-
Bayer to present new data from its hemophilia A portfolio at the International Society of Thrombosis and Haemostasis (ISTH) 2019 annual congress
6/26/2019
Bayer will present new data highlighting clinical outcomes from its hemophilia A portfolio, which include long-term data from the PROTECT VIII investigational study evaluating use of Jivi® antihemophilic factor PEGylated-aucl.
-
Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
6/19/2019
Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) has opened enrollment for patients with newly diagnosed and recurrent glioblastoma, the most aggressive and common form of primary brain cancer
-
Bayer Donates $50,000 to the Association of Foreign Correspondents in the United States
6/11/2019
New partnership to provide journalists with educational resources, grants and scholarships
-
Ranchland Managers Have a New Tool to Fight Invasive Annual Grass
6/10/2019
Esplanade® 200 SC herbicide Emergency Exemption is in place for Montana, Wyoming and Utah
-
The two companies will pair CStone’s CS1001 with Bayer’s regorafenib, an oral multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R and other receptors.
-
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
6/4/2019
Bayer announced a collaboration with Arvinas, Inc., a biopharmaceutical company based in New Haven, Connecticut.
-
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
-
New data on Vitrakvi® (larotrectinib) in TRK fusion cancer patients with brain metastases or primary central nervous system (CNS) tumors
6/3/2019
Bayer today announced results of a new analysis from clinical trials investigating Vitrakvi® (larotrectinib) in patients with TRK fusion cancer with primary central nervous system (CNS) tumors or brain metastases.
-
Bayer Receives U.S. FDA Breakthrough Therapy Designation for Aliqopa™ (copanlisib) for the Treatment of Marginal Zone Lymphoma
5/29/2019
Bayer announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for Aliqopa™ for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least two prior therapies.
-
Sensible Medical Innovations Licenses ReDS™ Technology to Bayer
5/28/2019
Sensible Medical Innovations and Bayer successfully signed an agreement making Bayer, Sensible's largest customer in Europe.
-
In addition to education and training, it will offer Bayer’s complete portfolio of recombinant Factor VIII treatments to healthcare providers in more than 60 countries.
-
Bayer Launches Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Help Propel Clinical Advancements Forward with up to 1 Million Dollars in Grants
5/20/2019
The PHAB Awards to be one of the largest industry-funded grant programs focused on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
-
Bayer presents new analyses for Vitrakvi® (larotrectinib) in adult and pediatric patients with TRK fusion cancer with solid tumors, and new data in primary central nervous system tumors and brain metastases
5/15/2019
Bayer announced findings from new analyses and data for Vitrakvi®, which is approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tropomyosin receptor kinase gene fusion without a known acquired resistance mutation that are either metastatic or where surgical resection will likely result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
-
Bayer, Grimmway Farms Bring Salad Bars to Rosedale Union Schools
5/15/2019
Investment Announced at Patriot Elementary as part of a Salad Bar Donation Ceremony and Carrot Variety Taste Test
-
Bayer said the award conflicts with an April report from the EPA that says glyphosate, the active ingredient in Roundup, is not a carcinogen.
-
Bayer statement on jury's decision in California State Glyphosate Trial
5/13/2019
Bayer released the following statement in reaction to a jury verdict in favor of the plaintiffs in the case of Pilliod v. Monsanto, a trial conducted before Judge Winifred Smith in the Superior Court of the State of California for the County of Alameda.
-
Bayer Data at ASCO 2019 Highlights Commitment to Evolving the Cancer Treatment Paradigm
5/13/2019
Bayer will present research from its expanding oncology portfolio at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago.
-
Divya Annamraju, Deputy Director of Strategy for Medical Devices Product Supply at Bayer, Honored as Healthcare Businesswomen's Association Luminary
5/10/2019
Divya Annamraju, Deputy Director of Strategy for Medical Devices Product Supply at Bayer, was honored as a Luminary by the Healthcare Businesswomen's Association at its annual Woman of the Year event, Thursday, May 9, at the Marriott Marquis in New York.